Research Article
PD-1/PD-L1 Inhibitors versus Chemotherapy for Previously Treated Advanced Gastroesophageal Cancer: A Meta-Analysis of Randomized Controlled Trials
Table 2
Characteristics of eligible studies included in the meta-analysis.
| | Trial | Geographic area | Tumor type | Year | Design | Medication | No. of patients | Clinical stage | Gender (M/F) | Median age (y) | PD-L1-positive patients | Line |
| | JAVELIN Gastric 300 | Europe, Asia, North America, and the rest of the world | GEJC/GC | 2018 | Phase 3 | Avelumab (10 mg/kg q2w) vs. chemotherapy (paclitaxel/irinotecan) | AVE: 185
CHE: 186 | NA | AVE: 140/45
CHE: 127/59 | AVE: 59 CHE: 61 | AVE: 46/157 (29.3%)
CHE: 39/160 (24.4%) | 2–3
(line3, 86%) | | KEYNOTE-061 | Europe, Asia, North
America, and the rest of the world | GEJC/GC | 2018 | Phase 3 | Pembrolizumab (200 mg q3w) vs. chemotherapy (paclitaxel) | PEM: 296
CHE: 296 | NA | PEM:
202/94
CHE:
208/88 | PEM: 62.5
CHE: 60.0 | PEM:
196/295 (66%)
CHE:
199/295 (67%) | 2 | | KEYNOTE-181 | Asia and the rest of the world | EC/GEJC | 2019 | Phase 3 | Pembrolizumab (200 mg q3w) vs. chemotherapy (paclitaxel/docetaxel/irinotecan) | PEM: 314
CHE: 314 | NA | PEM:
273/41
CHE:
271/43 | PEM: 63
CHE: 62 | PEM:
CPS≥10 (84); CPS<10 (89)
CHE:
CPS≥10 (84); CPS<10 (93) | 2 | | ATTRACTION-3 | Europe, East Asia, and the USA | ESCC | 2019 | Phase 3 | Nivolumab (240 mg q2w) vs. chemotherapy (paclitaxel/docetaxel) | NIV: 210
CHE: 209 | NIV : II-III: 8; IV: 94;
CHE : II–III: 13; IV: 100 | NIV: 179/31
CHE: 185/24 | NIV: 64
CHE: 67 | NIV: 101/210 (48%)
CHE: 102/209 (49%) | 2 | | ESCORT | East Asia | ESCC | 2020 | Phase 3 | Camrelizumab (200 mg q2w) vs. chemotherapy (docetaxel/irinotecan) | CAM: 228
CHE: 220 | NA | CAM: 208/20
CHE: 192/28 | CAM: 60
CHE: 60 | CAM: 93/222 (42%)
CHE: 98/216 (45%) | 2 | | ORIENT-2 | East Asia | ESCC | 2020 | Phase 2 | Sintilimab (200 mg q3w) vs. chemotherapy (paclitaxel/irinotecan | SIN: 95
CHE: 95 | SIN : III:7; IV:86
CHE : III: 6; IV: 89 | SIN: 88/7
CHE: 84/11 | SIN: 58.8
CHE: 59.4 | NA | 2 |
|
|
